Key result
Concurrent IV magnesium with dofetilide is linked to ~107% higher odds of successful AF/AFL cardioversion.
Why the study?
Whether intravenous magnesium enhances dofetilide's ability to chemically cardiovert patients from atrial fibrillation or flutter to normal sinus rhythm was not known.
Does intravenous magnesium improve successful chemical cardioversion in patients receiving dofetilide for persistent AF or AFL?
Population
160 patients in persistent AF or AFL receiving dofetilide at a single institution
Comparison
Dofetilide with intravenous magnesium vs dofetilide without intravenous magnesium
Design
Retrospective cohort evaluation
Follow-up
Minimum 3 days or 6 doses during hospital admission
Authors
Loading...
Does not support practice change; leaves open whether magnesium augments dofetilide success in prospective trials.
Cohort (n=160)
No
Does intravenous magnesium improve successful chemical cardioversion in patients receiving dofetilide for persistent AF or AFL?
Odds Ratio: 2.07 (95% CI 1–4.33)
Adjunctive intravenous magnesium significantly increases the odds of successful chemical cardioversion in patients receiving dofetilide for persistent atrial fibrillation or flutter.
Coleman et al. (2009) conducted a cohort in Atrial fibrillation or flutter (n=160). Intravenous magnesium sulfate vs. No intravenous magnesium was evaluated on Successful chemical cardioversion (OR 2.07, 95% CI 1.00-4.33). Concurrent administration of intravenous magnesium with dofetilide was associated with increased odds of successful chemical cardioversion of atrial fibrillation or flutter (OR 2.07; 95% CI 1.00-4.33).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: